BioStock Investor Pitch: Alligator Bioscience
How is Alligator Bioscience preparing to move forward after FDA approval? CEO Søren Bregenholt presents the company, which develops tumour-directed antibodies, and gives us the latest developments.
Watch the presentation below:
IMPORTANT INFORMATION
This material constitutes an introduction to the rights issue of units in Alligator (the ”Rights Issue”) and should be regarded as marketing material. The material is not and shall not be considered to constitute a prospectus in accordance with applicable laws and regulations. Invitation to shareholders and the public to subscribe for units in the Rights Issue takes place only through the prospectus that has been approved and registered by the Swedish Financial Supervisory Authority (the ”Prospectus”), and which has been published on www.alligatorbioscience.se/en/investors/preferential-rights-issue-q1-2024/. The Swedish Financial Supervisory Authority’s approval of the Prospectus shall not be construed as an approval of the new shares or warrants. In order for an investor to fully understand the potential risks and benefits associated with the decision to participate in the Rights Issue, any investment decision should only be made based on the information in the Prospectus. Investors are advised to read the full Prospectus.
The content of the article is sponsored by the company in question that appears in the text. BioStock does not provide investment advice, transmit investment orders and accepts no liability for any actions and/or any loss or damage of any kind based on the use of content published on BioStock.se. Instead, each investment decision is made independently by the individual investor.
